© 2025 MergersCorp M&A International.
© 2025 MergersCorp M&A International is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States.
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom.
Licensed Swiss Pharmaceutical Wholesale Business
This Licensed Pharmaceutical Wholesale Business is a pioneering organization in the pharmaceutical industry, committed to enhancing the quality of life through innovative healthcare solutions. Established with a vision to address unmet medical needs, the company exemplifies excellence in research and development, focusing on the creation of unique therapies that cater to rare and complex diseases.
A Swiss-registered pharmaceutical wholesaler holds a valuable Good Distribution Practice (GDP) authorization from Swissmedic. The company possesses comprehensive wholesale licensing for pharmaceutical products, enabling both national and international trade operations, including import, export, and raw materials wholesale activities. Operating with a small team from its Winterthur location, the business is structured to serve the global pharmaceutical market.
Strategic Value Proposition
The primary asset of the company is its GDP license, which acts as a significant barrier to entry in the pharmaceutical wholesale sector. Total investment to date amounts to CHF 230,566.18, covering complete operational setup and regulatory compliance. The business offers flexibility in acquisition structure, with options for a financed complete purchase.
Swiss Pharmaceutical Industry & Tax Advantages
Switzerland’s pharmaceutical sector is a premier global hub, home to industry leaders and renowned for its quality and regulatory excellence. A licensed operation benefits from this prestigious ecosystem, where pharmaceutical products command premium pricing and enjoy streamlined access to both EU and global markets. The Swiss regulatory framework, while stringent, offers significant advantages through mutual recognition agreements with major markets, facilitating international trade operations.
From a tax perspective, Switzerland provides compelling advantages for pharmaceutical operations. The country’s corporate tax rates are among Europe’s most competitive, typically ranging from 11.9% to 21.6%, depending on the canton. Switzerland’s patent box regime allows for preferential taxation of patent-related income, with up to 90% tax relief on qualifying income. Additionally, companies can benefit from R&D super-deductions and tax-efficient handling of intellectual property rights. The stability and transparency of the Swiss tax system, combined with an extensive network of double taxation treaties, create an optimal environment for international pharmaceutical trade and investment.
The GDP authorization’s scope covers comprehensive pharmaceutical wholesale operations, positioning the acquirer for immediate market entry into the regulated pharmaceutical distribution sector. While currently pre-revenue, the established regulatory framework and operational infrastructure provide a turnkey solution for entering the Swiss and international pharmaceutical wholesale market.
Keypoints
Registration Address: Winterthur, Swiss
Type of Entity: GmbH
Banking Relationship: Zürcher Kantonal Bank
Regulatory Licence: Swissmedic GDP
MergersCorp M&A
International As Seen On
Error: Contact form not found.
Error: Contact form not found.
Error: Contact form not found.
Error: Contact form not found.
Error: Contact form not found.
Description
This Licensed Pharmaceutical Wholesale Business is a pioneering organization in the pharmaceutical industry, committed to enhancing the quality of life through innovative healthcare solutions. Established with a vision to address unmet medical needs, the company exemplifies excellence in research and development, focusing on the creation of unique therapies that cater to rare and complex diseases.
A Swiss-registered pharmaceutical wholesaler holds a valuable Good Distribution Practice (GDP) authorization from Swissmedic. The company possesses comprehensive wholesale licensing for pharmaceutical products, enabling both national and international trade operations, including import, export, and raw materials wholesale activities. Operating with a small team from its Winterthur location, the business is structured to serve the global pharmaceutical market.
Strategic Value Proposition
The primary asset of the company is its GDP license, which acts as a significant barrier to entry in the pharmaceutical wholesale sector. Total investment to date amounts to CHF 230,566.18, covering complete operational setup and regulatory compliance. The business offers flexibility in acquisition structure, with options for a financed complete purchase.
Swiss Pharmaceutical Industry & Tax Advantages
Switzerland’s pharmaceutical sector is a premier global hub, home to industry leaders and renowned for its quality and regulatory excellence. A licensed operation benefits from this prestigious ecosystem, where pharmaceutical products command premium pricing and enjoy streamlined access to both EU and global markets. The Swiss regulatory framework, while stringent, offers significant advantages through mutual recognition agreements with major markets, facilitating international trade operations.
From a tax perspective, Switzerland provides compelling advantages for pharmaceutical operations. The country’s corporate tax rates are among Europe’s most competitive, typically ranging from 11.9% to 21.6%, depending on the canton. Switzerland’s patent box regime allows for preferential taxation of patent-related income, with up to 90% tax relief on qualifying income. Additionally, companies can benefit from R&D super-deductions and tax-efficient handling of intellectual property rights. The stability and transparency of the Swiss tax system, combined with an extensive network of double taxation treaties, create an optimal environment for international pharmaceutical trade and investment.
The GDP authorization’s scope covers comprehensive pharmaceutical wholesale operations, positioning the acquirer for immediate market entry into the regulated pharmaceutical distribution sector. While currently pre-revenue, the established regulatory framework and operational infrastructure provide a turnkey solution for entering the Swiss and international pharmaceutical wholesale market.
Keypoints
Registration Address: Winterthur, Swiss
Type of Entity: GmbH
Banking Relationship: Zürcher Kantonal Bank
Regulatory Licence: Swissmedic GDP
Basic Details
Target Price:
TBD
Gross Revenue
TBD
EBITDA
TBD
Business ID:
L#20250834
Country
Switzerland
City:
Winterthur
Detail
Similar Businesses
Published on February 7, 2025 at 9:24 pm. Updated on February 7, 2025 at 9:25 pm
Historical Pharma Manufacturing Business
$1,050,000,000
Pharma
Leading Research BioTech Company
TBA
Pharma
40-Year-Old MENA Pharmaceutical Manufacturing Company
$45,000,000
Pharma
40 Year Old Rx-pharma Manufacturing Business
$12,000,000
Manufacturing, Pharma
40 Year Old Pharmaceutical Manufacturing Business
$40,000,000
Manufacturing, Pharma
20-Year Old Pharmaceutical South American Brand
$11,500,000
Manufacturing, Pharma
PREVIOUS PROPERTY
Organic Food Producer and Exporter
NEXT PROPERTY
Professional League 3 Football Soccer Club